Clinical Drug Development At The Crossroads: One Drug, Multiple Indications

Portfolio Review and Strategic Decision Processing

Michael Murphy, MD, PhD

When a firm is developing a novel investigative product (IP) based on its effect on a particular molecular target or on its effect on a particular biomarker — rather than on its effect on a specific indication — there comes a point at which that developer needs to make decisions about directing and prioritizing its efforts. To make well-informed strategic decisions about how best to focus potentially divergent development efforts, decisionmakers need insight into all these matters. This is where a strategic portfolio review can play an important role in a development program. Read our white paper to learn more.

Your form has been successfully submitted! Click the button below to access.
Michael Murphy, MD, PhD

Michael Murphy, MD, PhD

Chief Medical and Scientific Officer